RE: Ophthalmology Times Article28 Feb 2024 20:30
“Non-viral, non-lipid delivery systems are in high demand in the exciting gene therapy and oncology spaces and we now have two such delivery systems,” Nigel Theobald, CEO of N4 Pharma, said in the company’s news release. “Nuvec continues to show its versatility as a novel delivery system and with LipTide we are developing our first commercial product which we are aiming to take into phase 1 clinical trials.”
'The company will now engage in discussions with the FDA and MHRA to approve a GLP toxicity study and first in human clinical trials.'